These findings emphasize the need for further studies investigating novel biomarkers that can predict EGFR TKI treatment efficacy, particularly the non-responders, and the primary mechanisms underlying resistance in NSCLC containing EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.